Oklahoma researchers battle resistant bacteria
from The Oklahoman
With E. coli diagnoses showing up across the United States, and even overseas, an Oklahoma research company's plans for an immune resistant antibiotic couldn't come at a better time. Biolytx Pharmaceuticals Corp. — an early-stage company based on the intellectual property of University of Oklahoma Health Sciences Center — is in the preclinical stages of producing an antibiotic that doctors will use to kill strains of increasingly resistant bacteria, said H. Anne Pereira, associate dean for research for the University of Oklahoma College of Pharmacy.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063